Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Use of bisphosphonates and reduced risk of colorectal cancer.

Rennert G, Pinchev M, Rennert HS, Gruber SB.

J Clin Oncol. 2011 Mar 20;29(9):1146-50. doi: 10.1200/JCO.2010.33.7485. Epub 2011 Feb 14.

2.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
3.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
4.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
5.

Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.

Liu Y, Zhao S, Chen W, Hu F, Zhu L, Zhang Q, Zhao Y.

Clin Breast Cancer. 2012 Aug;12(4):276-81. doi: 10.1016/j.clbc.2012.04.003. Epub 2012 May 22. Review.

PMID:
22622199
6.

[Bisphosphonates and breast cancer].

Vehmanen L, Saarto T.

Duodecim. 2010;126(10):1229-37. Review. Finnish.

PMID:
20597352
7.

Bisphosphonates for advanced prostate cancer.

Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006250. Review.

PMID:
17054286
8.

[Current use of bisphosphonates in clinical oncology].

Vrbanec D, Plestina S, Belev B, Unusić J, Pavlinić-Diminić V.

Lijec Vjesn. 1999 Sep-Oct;121(9-10):296-301. Review. Croatian.

PMID:
19658372
9.

Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

Lipton A.

Breast Cancer Res Treat. 2010 Aug;122(3):627-36. doi: 10.1007/s10549-010-0935-7. Epub 2010 May 21. Review.

PMID:
20490653
10.

Optimal management of metastatic bone disease.

Major P.

Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7. Epub 2007 Sep 4. Review.

PMID:
17804294
11.

Bisphosphonates as treatment of bone metastases.

Holen I, Coleman RE.

Curr Pharm Des. 2010;16(11):1262-71. Review.

PMID:
20166976
12.

Prevention of bone metastases and management of bone health in early breast cancer.

Gnant M, Hadji P.

Breast Cancer Res. 2010;12(6):216. doi: 10.1186/bcr2768. Epub 2010 Dec 17. Review.

13.

Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.

Gnant M.

Breast Dis. 2011;33(2):71-81. doi: 10.3233/BD-2010-0325. Review.

PMID:
22142663
14.

Bisphosphonates and breast cancer incidence and recurrence.

Chlebowski RT, Col N.

Breast Dis. 2011;33(2):93-101. doi: 10.3233/BD-2010-0324. Review.

PMID:
22142660
15.

[Treatment of bone metastases with bisphosphonates].

Gremaud M, Delouche D, Monnerat C.

Rev Med Suisse. 2006 Aug 9;2(75):1861-6. Review. French.

PMID:
16948423
16.

Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.

Oh YH, Yoon C, Park SM.

World J Gastroenterol. 2012 Oct 28;18(40):5779-88. doi: 10.3748/wjg.v18.i40.5779. Review.

18.

[Bisphosphonates in oncology].

Kurth AA, Heidenreich A, Diel I.

Orthopade. 2007 Feb;36(2):131-5. Review. German.

PMID:
17252255
19.

Effects of bone-targeted agents on cancer progression and mortality.

Coleman R, Gnant M, Morgan G, Clezardin P.

J Natl Cancer Inst. 2012 Jul 18;104(14):1059-67. doi: 10.1093/jnci/djs263. Epub 2012 Jul 2. Review.

PMID:
22752060
20.

Role of bisphosphonates in postmenopausal women with breast cancer.

Gnant M.

Cancer Treat Rev. 2014 Apr;40(3):476-84. doi: 10.1016/j.ctrv.2013.07.003. Epub 2013 Jul 29. Review.

PMID:
23906846

Supplemental Content

Support Center